American Society of Gene Therapy Annual Meeting (2009-2013)

描述(由申请人提供)： 美国基因治疗学会成立于1996年，致力于基因和细胞治疗的发展，特别关注专业和公共教育。我们的年会代表了协会的主要教育倡议，并在我们之前的11次会议上都获得了CME认证。这份R13提案要求为旅行补助和培训生的教育计划提供支持。我们超过四分之一的成员是正在接受培训的科学家，他们致力于开发临床适用的基于基因的技术。学员参加年会是由杰出的教育项目、学员旅行奖励以及通过同行评审的学员卓越研究奖来表彰杰出的科学成就而促成的。在过去的十年里，ASGT已经提供了470个旅行补助金和63个研究奖，其中在过去5年中，通过NHLBI提供的R13赠款，每年提供20个旅行补助金。旅游奖获得者的教育机会包括杰出的全体演讲者、最先进的科学研讨会，以及审查各种主题当前思维的教育会议。除了顶尖的科学家和临床医生，该计划还包括伦理学家和来自FDA、OBA和NIH的代表，因此年轻科学家可以深入了解与人类基因治疗相关的合规和伦理问题。受训人员是口头摘要和海报演示的活跃演讲者，顶尖受训人员摘要在总统研讨会上得到表彰。该提案还要求部分支持一项新颖的“会见专家”计划，该计划允许受训者在小组环境中与基因治疗负责人互动。ASGT会议的规模(约2,000人参加)非常适合让年轻科学家接触该领域的领导者，同时也为受训人员在基因和细胞治疗领域的首要会议上展示他们的工作提供了机会。NIH对ASGT年会的持续支持将使受训人员在细胞和基因治疗领域继续获得教育和专业上的进步。(摘要结束)

DESCRIPTION (provided by applicant): The American Society of Gene Therapy was founded in 1996 and is dedicated to the development of gene and cell therapies with a particular focus on professional and public education. Our Annual Meeting represents the major educational initiative of the Society and has been CME accredited for all of our prior 11 meetings. This R13 proposal requests support for travel grants and an educational program for trainees. Over 1/4 of our members are scientists in training working to develop clinically applicable gene-based technologies. Trainee participation in the Annual Meeting is fostered by an outstanding educational program, trainee travel awards, and recognition of outstanding scientific accomplishments through peer-reviewed trainee Excellence in Research Awards. Over the past decade, the ASGT has offered 470 travel grants and 63 Research Awards, with 20 travel grants per year for the past 5 years made possible by an R13 grant from the NHLBI. Educational opportunities for travel awardees include outstanding plenary speakers, state-of-the-art scientific symposia, and educational sessions that review current thinking on a variety of topics. In addition to leading scientists and clinicians, the program includes ethicists and representatives from the FDA, OBA, and NIH so young scientists may gain insight into the compliance and ethical issues related to human gene therapy. Trainees are active presenters in oral abstract and poster presentations and the top trainee abstracts are recognized at the Presidential Symposium. This proposal also requests partial support of a novel "Meet the Expert" program that allows trainees to interact with gene therapy leaders in a small group setting. The size of the ASGT meeting (approximately 2,000 participants) is ideally suited to expose young scientists to leaders in the field, yet provide opportunities for trainees to present their work at the premier meeting in the field of gene and cell therapy. Continued NIH support for the ASGT Annual Meeting will allow continued educational and professional advancement of trainees in the field of cell and gene therapy. (End of Abstract)